BMY vs. MRK, ABBV, PFE, ZTS, RPRX, JAZZ, PRGO, CORT, SUPN, and PCRX
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.
Merck & Co., Inc. (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.
Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.8%. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Bristol-Myers Squibb has raised its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Bristol-Myers Squibb received 110 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. However, 67.01% of users gave Merck & Co., Inc. an outperform vote while only 66.89% of users gave Bristol-Myers Squibb an outperform vote.
In the previous week, Bristol-Myers Squibb had 3 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 23 mentions for Bristol-Myers Squibb and 20 mentions for Merck & Co., Inc.. Bristol-Myers Squibb's average media sentiment score of 0.89 beat Merck & Co., Inc.'s score of 0.71 indicating that Merck & Co., Inc. is being referred to more favorably in the media.
Merck & Co., Inc. currently has a consensus price target of $133.00, suggesting a potential upside of 1.78%. Bristol-Myers Squibb has a consensus price target of $60.00, suggesting a potential upside of 44.65%. Given Merck & Co., Inc.'s higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Merck & Co., Inc..
Merck & Co., Inc. has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.
76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.1% of Merck & Co., Inc. shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Merck & Co., Inc. has a net margin of 3.76% compared to Merck & Co., Inc.'s net margin of -13.50%. Bristol-Myers Squibb's return on equity of 14.05% beat Merck & Co., Inc.'s return on equity.
Bristol-Myers Squibb has lower revenue, but higher earnings than Merck & Co., Inc.. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Summary
Merck & Co., Inc. beats Bristol-Myers Squibb on 12 of the 21 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
